Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRα) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a Drug-to-antibody ratio (DAR) of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity. This product is for research use only.
Product Details |
Species Reactivity | Human |
---|
Type | Antibody-drug conjugate |
---|
ADC antibody | Farletuzumab (anti-FRα) |
---|
ADC cytotoxin (drug) | MMAE |
---|
Immunogen | Human folate receptor alpha (FRα) |
---|
DAR (Drug to Antibody Ratio) | 4 |
---|
Purity | 99% |
---|
Molecular Weight | 149kDa |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | 1xPBS |